



## Viatriis Issues Statement on S&P Credit Rating Change

February 28, 2025

**PITTSBURGH, February 28, 2025** –[Viatriis Inc](#) (NASDAQ: VTRS) today received notice that S&P Global Ratings downgraded Viatriis' credit rating from BBB- to BB+ with a stable outlook.

The Company's intention is to continue the capital allocation plan described in its February 27, 2025, earnings call.

### About Viatriis

Viatriis Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatriis. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at [viatriis.com](#) and [investor.viatriis.com](#), and connect with us on LinkedIn, Instagram, YouTube and X.

### Forward-Looking Statements

This statement includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding the Company's credit rating and that the Company's intention is to continue the capital allocation plan described in its February 27, 2025, earnings call. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatriis' ability to bring new products to market; Viatriis' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; Viatriis' failure to achieve expected or targeted future financial and operating performance and results; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatriis' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatriis or its partners; uncertainties and matters beyond the control of management, including general economic conditions, tariffs and trade policies, inflation and exchange rates; and the other risks described in Viatriis' filings with the Securities and Exchange Commission (SEC). Viatriis routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatriis undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.

### Contacts:

#### MEDIA

+1.724.514.1968

[Communications@viatriis.com](mailto:Communications@viatriis.com)

Jennifer Mauer

[Jennifer.Mauer@viatriis.com](mailto:Jennifer.Mauer@viatriis.com)

Matt Klein

[Matthew.Klein@viatriis.com](mailto:Matthew.Klein@viatriis.com)

#### INVESTORS

+1.724.514.1813

[InvestorRelations@viatriis.com](mailto:InvestorRelations@viatriis.com)

Bill Szablewski

[William.Szablewski@viatriis.com](mailto:William.Szablewski@viatriis.com)

Jill Sawyer

[Jill.Sawyer@viatriis.com](mailto:Jill.Sawyer@viatriis.com)